Revolution Medicines/$RVMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Revolution Medicines
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
Ticker
$RVMD
Sector
Primary listing
Employees
700
Headquarters
Website
RVMD Metrics
BasicAdvanced
$8.7B
-
-$4.53
1.16
-
Price and volume
Market cap
$8.7B
Beta
1.16
52-week high
$60.59
52-week low
$29.17
Average daily volume
2.1M
Financial strength
Current ratio
11.794
Quick ratio
11.581
Long term debt to equity
6.417
Total debt to equity
7.119
Profitability
EBITDA (TTM)
-890.7
Effective tax rate (TTM)
0.09%
Management effectiveness
Return on assets (TTM)
-26.47%
Return on equity (TTM)
-46.61%
Valuation
Price to book
4.66
Price to tangible book (TTM)
4.85
Price to free cash flow (TTM)
-11.927
Free cash flow yield (TTM)
-8.38%
Free cash flow per share (TTM)
-3.903
Growth
Earnings per share change (TTM)
26.53%
3-year earnings per share growth (CAGR)
14.24%
What the Analysts think about RVMD
Analyst ratings (Buy, Hold, Sell) for Revolution Medicines stock.
Bulls say / Bears say
The FDA granted Breakthrough Therapy Designation to daraxonrasib for previously treated metastatic PDAC with KRAS G12 mutations on June 23, 2025, potentially speeding up its development and review process.
Revolution Medicines dosed the first patient in the pivotal Phase 3 RASolve 301 trial for previously treated RAS-mutant NSCLC on May 14, 2025, marking a major step toward completing a registrational study.
The company secured a $2 billion flexible funding agreement with Royalty Pharma on June 24, 2025, including up to $1.25 billion in synthetic royalty financing and $750 million in debt to support global development and commercialization, while retaining strategic control.
The company reported Q2 2025 revenue of $0, missing analyst expectations of $30.6 million and highlighting its lack of approved products to drive near-term revenue.
Revolution Medicines’ cash burn increased in Q2 2025, with R&D expenses rising to $224.1 million and G&A expenses up to $40.6 million, resulting in a net loss of $247.8 million. This accelerates the risk of future funding needs despite a current cash runway through mid-2027.
Key Phase 3 data for daraxonrasib aren’t expected until 2026, creating a long catalyst gap and exposing investors to binary clinical risk without near-term updates.
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.
RVMD Financial Performance
Revenues and expenses
RVMD Earnings Performance
Company profitability
RVMD News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Revolution Medicines stock?
Revolution Medicines (RVMD) has a market cap of $8.7B as of September 15, 2025.
What is the P/E ratio for Revolution Medicines stock?
The price to earnings (P/E) ratio for Revolution Medicines (RVMD) stock is 0 as of September 15, 2025.
Does Revolution Medicines stock pay dividends?
No, Revolution Medicines (RVMD) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Revolution Medicines dividend payment date?
Revolution Medicines (RVMD) stock does not pay dividends to its shareholders.
What is the beta indicator for Revolution Medicines?
Revolution Medicines (RVMD) has a beta rating of 1.16. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.